MRK · News · 20260910N
Product / Drug Pipeline Progress
Merck & Co., Inc. · 2026-09-10 · Importance 72 · Surprise 74 · From source text
Merck is targeting a $70 billion human-health revenue pipeline by the mid-2030s to offset the eventual loss of exclusivity for KEYTRUDA. The pipeline focus spans oncology, including antibody-drug conjugates, as well as cardiometabolic disease, ophthalmology, immunology, and HIV. Merck expects newer products and the Animal Health business to help offset generic competition after KEYTRUDA exclusivity loss, resulting in a gradual revenue decline rather than a sharp cliff.
Key facts
- Merck increased its earlier pipeline target from $50 billion to $70 billion. source
- Merck plans to achieve the $70 billion pipeline target through strategic investments across oncology, cardiometabolic disease, ophthalmology, immunology, and HIV, alongside targeted acquisitions and new product launches. source
- Merck is expanding its pipeline with antibody-drug conjugates (ADCs). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | +60.2% | Merck increased its earlier pipeline target from $50 billion to $70 billion. |
| operating_income | negative | probable | — | Merck plans to achieve the $70 billion pipeline target through strategic investments across oncology, cardiometabolic disease,… |
| cash | negative | contingent | — | Merck plans to achieve the $70 billion pipeline target through strategic investments across oncology, cardiometabolic disease,… |
| revenue | positive | contingent | — | Merck is expanding its pipeline with antibody-drug conjugates (ADCs). |